Literature DB >> 27892929

A review of kinase fusions in melanocytic tumors.

Sara C Shalin1.   

Abstract

Translocations resulting in a kinase fusion are well reported in many tumor types and indeed can be defining, particularly in the case of hematopoietic malignancies. The recent reports of multiple protein kinase fusions within melanocytic neoplasms, particularly in those with spitzoid morphology, have heralded a new era of classification of these melanocytic tumors. Seen within approximately half of all spitzoid neoplasms and present within the full spectrum of benign, atypical, and malignant lesions, kinase fusions likely represent an early oncogenic event contributing to cell proliferation and growth. Although the presence of a kinase fusion does not seem to correlate with the biologic potential of a given lesion, documentation of a kinase fusion will likely be important, particularly in the case of spitzoid melanoma, as numerous specific kinase receptor inhibitors have shown promise as therapeutic agents in a subset of cases with kinase fusions. Interrogation of non-spitzoid melanomas for similar kinase fusions as a potential driving oncogenic mechanism has revealed some similarities and some differences. This review will focus on the kinase fusions described to date in spitzoid neoplasms and how subsequent studies have informed current melanoma research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27892929     DOI: 10.1038/labinvest.2016.122

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  22 in total

1.  Genomic Rearrangements in Unusual and Atypical Melanocytic Neoplasms.

Authors:  Thomas Wiesner
Journal:  JAMA Dermatol       Date:  2016-03       Impact factor: 10.282

2.  ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.

Authors:  Leona A Doyle; Adrián Mariño-Enriquez; Christopher D M Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-04-10       Impact factor: 7.842

3.  Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.

Authors:  Alexander M Menzies; Iwei Yeh; Thomas Botton; Boris C Bastian; Richard A Scolyer; Georgina V Long
Journal:  Pigment Cell Melanoma Res       Date:  2015-07-03       Impact factor: 4.693

4.  Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.

Authors:  Iwei Yeh; Arnaud de la Fouchardiere; Daniel Pissaloux; Thaddeus W Mully; Maria C Garrido; Swapna S Vemula; Klaus J Busam; Philip E LeBoit; Timothy H McCalmont; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

Review 5.  Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.

Authors:  Thomas Wiesner; Heinz Kutzner; Lorenzo Cerroni; Martin C Mihm; Klaus J Busam; Rajmohan Murali
Journal:  Pathology       Date:  2016-01-18       Impact factor: 5.306

Review 6.  ROS1 fusions in cancer: a review.

Authors:  Arnaud Uguen; Marc De Braekeleer
Journal:  Future Oncol       Date:  2016-06-03       Impact factor: 3.404

7.  Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.

Authors:  Hai-Tao Niu; Qi-Ming Zhou; Fang Wang; Qiong Shao; Yuan-Xiang Guan; Xi-Zhi Wen; Li-Zhen Chen; Qi-Sheng Feng; Wei Li; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  Pigment Cell Melanoma Res       Date:  2013-07-11       Impact factor: 4.693

8.  TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.

Authors:  Seungjae Lee; Raymond L Barnhill; Reinhard Dummer; James Dalton; Jianrong Wu; Alberto Pappo; Armita Bahrami
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

9.  Activating MET kinase rearrangements in melanoma and Spitz tumours.

Authors:  Iwei Yeh; Thomas Botton; Eric Talevich; A Hunter Shain; Alyssa J Sparatta; Arnaud de la Fouchardiere; Thaddeus W Mully; Jeffrey P North; Maria C Garrido; Alexander Gagnon; Swapna S Vemula; Timothy H McCalmont; Philip E LeBoit; Boris C Bastian
Journal:  Nat Commun       Date:  2015-05-27       Impact factor: 14.919

10.  The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.

Authors:  Jeffrey S Ross; Kai Wang; Juliann Chmielecki; Laurie Gay; Adrienne Johnson; Jacob Chudnovsky; Roman Yelensky; Doron Lipson; Siraj M Ali; Julia A Elvin; Jo-Anne Vergilio; Steven Roels; Vincent A Miller; Brooke N Nakamura; Adam Gray; Michael K Wong; Philip J Stephens
Journal:  Int J Cancer       Date:  2015-09-08       Impact factor: 7.396

View more
  2 in total

Review 1.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

2.  Expanding spectrum of "spitzoid" lesions: a small series of 4 cases with MAP2K1 mutations.

Authors:  K G P Kerckhoffs; T Aallali; C A Ambarus; V Sigurdsson; A M L Jansen; W A M Blokx
Journal:  Virchows Arch       Date:  2020-10-11       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.